This Promising Weight Loss Drug Candidate Could Be a Huge Growth Catalyst for Pfizer
https://www.fool.com/investing/2024/07/24/this-promising-weight-loss-drug-candidate-could-be/?source=iedfolrf0000001
Jul 24, 2024 - With danuglipron, Pfizer could become a major player in the massive GLP-1 agonist market.
0
PFE or NVO: Which Is the Better Value Stock Right Now?
https://www.zacks.com/stock/news/2300998/pfe-or-nvo-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2300998
Jul 12, 2024 - PFE vs. NVO: Which Stock Is the Better Value Option?
0
Pharma Stock Roundup: LLY to Buy Morphic, PFE Advances Obesity Drug Development
https://www.zacks.com/stock/news/2300869/pharma-stock-roundup-lly-to-buy-morphic-pfe-advances-obesity-drug-development?cid=CS-ZC-FT-analyst_blog|stock_roundup-2300869
Jul 12, 2024 - Eli Lilly (LLY) offers to acquire Morphic Therapeutics for $3.2 billion. Pfizer (PFE) selects a once-daily formulation of danuglipron for further development as a weight loss pill.
0
Top Analyst Reports for Danaher, Morgan Stanley & Pfizer
https://www.zacks.com/commentary/2299883/top-analyst-reports-for-danaher-morgan-stanley-pfizer?cid=CS-ZC-FT-research_daily-2299883
Jul 11, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Danaher Corporation (DHR), Morgan Stanley (MS) and Pfizer Inc. (PFE), as well as two micro-cap stocks, Elite Pharmaceuticals, Inc. (ELTP) and Oil-Dri Corporation of America (ODC).
0
4 stocks to watch on Thursday: PEP, PFE and more
https://seekingalpha.com/news/4123669-4-stocks-to-watch-on-thursday-pep-pfe-and-more?source=feed_sector_healthcare
Jul 11, 2024 - PepsiCo (PEP), Conagra Brands (CAG), Delta Air Lines (DAL) and Pfizer (PFE) are the stocks to watch on Thursday. Read more here.
0
Is GSK an Attractive Drug Stock to Add to Your Portfolio Now?
https://www.zacks.com/stock/news/2299157/is-gsk-an-attractive-drug-stock-to-add-to-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2299157
Jul 10, 2024 - Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates make the stock attractive
0
2 Ultra-High-Yield Dividend Stocks Billionaires Are Buying Left and Right: Could They Be Smart Buys for You in July?
https://www.fool.com/investing/2024/06/30/2-ultra-high-yield-dividend-stocks-billionaires-ar/?source=iedfolrf0000001
Jun 30, 2024 - With an average dividend yield of about 9.8% at recent prices, even a small investment in these stocks could significantly boost your passive income stream.
0
CDC Narrows Age Recommendation for Use of RSV Vaccine
https://www.zacks.com/stock/news/2295178/cdc-narrows-age-recommendation-for-use-of-rsv-vaccine?cid=CS-ZC-FT-analyst_blog|industry_focus-2295178
Jun 28, 2024 - The U.S. CDC recommends that adults aged 75 years and above get an RSV shot. Those aged 60 to 74 years should only get the shot if they are at high risk for severe RSV due to chronic conditions.
0
Moderna (MRNA) Shares Decline on RSV Vaccine Efficacy Data
https://www.zacks.com/stock/news/2294523/moderna-mrna-shares-decline-on-rsv-vaccine-efficacy-data?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2294523
Jun 27, 2024 - Moderna (MRNA) stock sinks after new data shows the efficacy of its mRNA-based RSV vaccine fell sharply in the second year and was lower than that of rival vaccines marketed by GSK and Pfizer.
0
This Recent FDA Approval Is Bad News for Pfizer
https://www.fool.com/investing/2024/06/27/this-recent-fda-approval-is-bad-news-for-pfizer/?source=iedfolrf0000001
Jun 27, 2024 - One of the pharma giant's top-selling products is about to face some intense competition.
0